Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
Senseonics Holdings (NYSE: SENS) has announced a public offering of common stock aiming to raise $50 million, along with a concurrent private placement. The company will grant underwriters a 30-day option to purchase an additional 15% of the total shares offered. Abbott Laboratories has agreed to purchase up to $25 million of shares in a separate private placement at the public offering price.
The offering is being managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners. The proceeds will be used to fund the ongoing launch of Eversense 365, continue pipeline product development, and support working capital and general corporate purposes.
Senseonics Holdings (NYSE: SENS) ha annunciato un'offerta pubblica di azioni ordinarie con l'obiettivo di raccogliere 50 milioni di dollari, accompagnata da un collocamento privato simultaneo. La società concederà agli underwriter un'opzione di 30 giorni per acquistare un ulteriore 15% delle azioni totali offerte. Abbott Laboratories ha accettato di acquistare fino a 25 milioni di dollari di azioni in un collocamento privato separato al prezzo dell'offerta pubblica.
L'offerta è gestita da TD Cowen e Barclays come joint book-running manager, con RBC Capital Markets e Lake Street come bookrunner. I proventi saranno utilizzati per finanziare il lancio in corso di Eversense 365, per continuare lo sviluppo dei prodotti in pipeline e per supportare il capitale circolante e le finalità aziendali generali.
Senseonics Holdings (NYSE: SENS) ha anunciado una oferta pública de acciones ordinarias con el objetivo de recaudar 50 millones de dólares, junto con una colocación privada simultánea. La compañía otorgará a los suscriptores una opción de 30 días para comprar un 15% adicional del total de acciones ofrecidas. Abbott Laboratories ha acordado comprar hasta 25 millones de dólares en acciones en una colocación privada separada al precio de la oferta pública.
La oferta está siendo gestionada por TD Cowen y Barclays como gestores conjuntos principales, con RBC Capital Markets y Lake Street como colocadores. Los fondos se usarán para financiar el lanzamiento en curso de Eversense 365, continuar con el desarrollo de productos en cartera y apoyar el capital de trabajo y los fines corporativos generales.
Senseonics Holdings (NYSE: SENS)는 5,000만 달러를 조달하기 위한 보통주 공개 모집과 동시에 사모 발행을 발표했습니다. 회사는 인수인들에게 총 발행 주식의 추가 15%를 30일간 매수할 수 있는 옵션을 부여할 예정입니다. Abbott Laboratories는 공개 모집 가격으로 별도의 사모 발행에서 최대 2,500만 달러 상당의 주식을 매입하기로 합의했습니다.
이번 공모는 TD Cowen과 Barclays가 공동 주관사로, RBC Capital Markets와 Lake Street가 주관사로 참여하고 있습니다. 조달된 자금은 Eversense 365의 지속적인 출시, 파이프라인 제품 개발, 운전자본 및 일반 기업 목적 지원에 사용될 예정입니다.
Senseonics Holdings (NYSE : SENS) a annoncé une offre publique d'actions ordinaires visant à lever 50 millions de dollars, accompagnée d'un placement privé simultané. La société accordera aux souscripteurs une option de 30 jours pour acheter 15 % supplémentaires des actions totales proposées. Abbott Laboratories a accepté d'acheter jusqu'à 25 millions de dollars d'actions dans un placement privé distinct au prix de l'offre publique.
L'offre est gérée par TD Cowen et Barclays en tant que co-chefs de file, avec RBC Capital Markets et Lake Street comme teneurs de livre. Les fonds seront utilisés pour financer le lancement en cours de Eversense 365, poursuivre le développement des produits en pipeline et soutenir le fonds de roulement ainsi que les besoins généraux de l'entreprise.
Senseonics Holdings (NYSE: SENS) hat eine öffentliche Aktienemission angekündigt, mit dem Ziel, 50 Millionen US-Dollar zu beschaffen, sowie eine gleichzeitige Privatplatzierung. Das Unternehmen gewährt den Underwritern eine 30-tägige Option zum Erwerb von zusätzlich 15 % der insgesamt angebotenen Aktien. Abbott Laboratories hat zugestimmt, im Rahmen einer separaten Privatplatzierung Aktien im Wert von bis zu 25 Millionen US-Dollar zum Preis der öffentlichen Emission zu kaufen.
Die Emission wird von TD Cowen und Barclays als gemeinsame Bookrunner geleitet, mit RBC Capital Markets und Lake Street als Co-Bookrunner. Die Erlöse werden verwendet, um die laufende Markteinführung von Eversense 365 zu finanzieren, die Produktentwicklung in der Pipeline fortzusetzen sowie das Betriebskapital und allgemeine Unternehmenszwecke zu unterstützen.
- Strategic partnership with Abbott Laboratories demonstrated through their $25 million commitment
- Funds will support the launch of Eversense 365 and pipeline development
- Multiple reputable financial institutions involved as underwriters
- Potential dilution of existing shareholders' value
- Share offering may put downward pressure on stock price
- Additional shares in the market through the 15% overallotment option could further impact dilution
Insights
Senseonics is diluting shareholders through a $50M public offering and $25M Abbott placement to fund product launches and development.
Senseonics Holdings has announced a significant capital raising strategy consisting of a $50 million public offering of common stock and a $25 million concurrent private placement with Abbott Laboratories. This dual-pronged financing approach will inject a total of $75 million into the company, providing substantial liquidity but also diluting existing shareholders.
The structure of this deal is particularly noteworthy. The public offering gives underwriters a 30-day option to purchase an additional 15% of shares, potentially increasing dilution beyond the initial offering. Meanwhile, the private placement with Abbott strengthens an existing strategic relationship, as Abbott has committed to purchasing shares at the same price as the public offering.
The company has clearly articulated its use of proceeds: funding the ongoing launch of Eversense 365 (their extended-wear CGM system) and continued development of pipeline products. This indicates that Senseonics is prioritizing commercial expansion and R&D investment over near-term profitability.
The timing of this capital raise suggests Senseonics needs additional funding to sustain operations and execute its growth strategy. For a medical technology company focused on implantable continuous glucose monitoring systems, substantial capital is required for both commercial scaling and ongoing product innovation to compete in the highly competitive diabetes management market.
The involvement of four investment banks (TD Cowen, Barclays, RBC Capital Markets, and Lake Street) as underwriters suggests institutional support for the offering, though the final terms and price aren't disclosed yet, meaning the actual level of dilution remains uncertain until the final prospectus is filed.
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional
TD Cowen and Barclays are acting as joint book-running managers and RBC Capital Markets and Lake Street are acting as bookrunners for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
The proposed offering is being made pursuant to a “shelf” registration statement on Form S-3, including a base prospectus (File No. 333-273882) that was originally filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2023 and became effective on September 12, 2023. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at TD.ECM_Prospectus@tdsecurities.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@broadridge.com.
Pursuant to the terms of a Securities Purchase Agreement with Abbott Laboratories (“Abbott”), Abbott has agreed to purchase up to
Senseonics intends to use the net proceeds from the public offering and the Concurrent Private Placement to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes.
Before investing in the offering, you should read the preliminary prospectus supplement and related prospectus for the offering, including the documents incorporated by reference therein, that Senseonics has filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, the size of the proposed offering; Senseonics’ expectations about the completion and timing of the proposed offering and anticipated use of proceeds from the proposed offering and the Concurrent Private Placement; and Senseonics’ expectations with respect to granting the underwriters a 30-day option to purchase additional shares. The words “expects,” “potential,” “proposed,” “may,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to Senseonics’ inability, or the inability of underwriters, to satisfy the conditions to closing for the proposed offering; failure to satisfy the closing conditions of the Concurrent Private Placement; uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics’ actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
INVESTOR CONTACT:
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
How much is Senseonics (SENS) planning to raise in their 2025 stock offering?
What will Senseonics use the proceeds from their 2025 stock offering for?
Who are the underwriters for Senseonics' 2025 public offering?
How much is Abbott Laboratories investing in Senseonics' 2025 private placement?
What additional options are being offered to underwriters in Senseonics' 2025 stock offering?
